$SanBio (4592.JP)$Significantly rebounded. The Ministry of Health, Labour and Welfare's holding of the Regenerative Medicine and Bioengineering Subcommittee from 6 p.m. on the 19th is becoming a buying clue. SanBio's development product SB623 is included as an agenda item, stating the approval of manufacturing and sales, conditions and deadlines, and the need for re-examination period. It seems that there is an expectation that manufacturing and sales will be approved at the same subcommittee, making buying advantageous.
サンバイオ---大幅に反発、再生医療等製品の製造販売承認に期待、薬事審議会で部会開催へ
SanBio - Significantly rebounded, expecting approval for manufacturing and sales of regenerative medicine products, subcommittee to be held at the Pharmaceutical Affairs Council.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.